1. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. (July 2021) Authors: O'Shaughnessy, Joyce; Sousa, Susana; Cruz, Josefina; Fallowfield, Lesley; Auvinen, Päivi; Pulido, Catarina; Cvetanovic, Ana; Wilks, Sharon; Ribeiro, Leonor; Burotto, Mauricio; Klingbiel, Dirk; Messeri, Dimitri; Alexandrou, Ari; Trask, Peter; Fredriksson, Judy; Machackova, Zuzana; Stamatovic, Ljil... Journal: European journal of cancer Issue: Volume 152(2021) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study. Issue 5 (10th February 2022) Authors: Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Hervé; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiy... Journal: Journal of clinical oncology Issue: Volume 40:Issue 5(2022) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗